<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02340715</url>
  </required_header>
  <id_info>
    <org_study_id>Advanced MRI</org_study_id>
    <nct_id>NCT02340715</nct_id>
  </id_info>
  <brief_title>Advanced MRI Sequences for Radiation Therapy Treatment Planning</brief_title>
  <official_title>Investigation on the Utility of Advanced MRI Imaging Methods for Radiation Therapy Treatment Planning</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical College of Wisconsin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical College of Wisconsin</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if it would be helpful to use advanced MRI imaging
      techniques to take additional views of the tumor target for radiation treatment planning or
      treatment follow-up MRI.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The results of this research project will be used to establish a standard MRI protocol
      specific to each tumor or disease site. An MRI protocol is a list of MR image types that are
      acquired for each disease site. These images are used to generate the patient's treatment
      plan.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Successfully Contributing MRI Data</measure>
    <time_frame>up to 4 weeks from imaging</time_frame>
    <description>We tested these Advanced MR protocols to evaluate which ones would best visualize the target region. This helped us determine the optimum MR SIM protocols for different sites that became clinical standard.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">158</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>MRI for treatment planning or follow up</arm_group_label>
    <description>MRI for treatment planning for radiation therapy or those who have completed treatment and are receiving follow up care.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects who are planning to have radiation therapy for their cancer.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged 18 years older of any race or gender with anal canal, brain, breast,
             cervix, esophagus, gynecology, head and neck, lung, pancreas, primary liver or liver
             metastases, prostate cancer or sarcoma either undergoing MRI scan for radiation
             treatment planning or a post treatment MRI

          -  Voluntarily signs an IRB approved consent form

        Exclusion Criteria:

          -  Inability to obtain informed consent from the patient or their medical power of
             attorney

          -  Patients who are not undergoing MR for radiation treatment planning

          -  Patients who will not have MRI scans after treatment

          -  Patients with pacemakers or other non-MRI compatible metallic implants

          -  Pregnant women, by self report using a standard MRI questionnaire

          -  Patients who will not receive contrast agent as part of their standard MR, will
             participate only in the non-contrast portion of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ergun Ahunbay, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical College of Wisconsin</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Froedtert Hospital</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Khoo VS, Dearnaley DP, Finnigan DJ, Padhani A, Tanner SF, Leach MO. Magnetic resonance imaging (MRI): considerations and applications in radiotherapy treatment planning. Radiother Oncol. 1997 Jan;42(1):1-15. Review.</citation>
    <PMID>9132820</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 10, 2014</study_first_submitted>
  <study_first_submitted_qc>January 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 19, 2015</study_first_posted>
  <results_first_submitted>May 22, 2017</results_first_submitted>
  <results_first_submitted_qc>October 30, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">October 31, 2017</results_first_posted>
  <last_update_submitted>October 30, 2017</last_update_submitted>
  <last_update_submitted_qc>October 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical College of Wisconsin</investigator_affiliation>
    <investigator_full_name>AhunbayE</investigator_full_name>
    <investigator_title>Chief of Physics</investigator_title>
  </responsible_party>
  <keyword>Anal canal</keyword>
  <keyword>Brain</keyword>
  <keyword>Breast</keyword>
  <keyword>Cervix</keyword>
  <keyword>Esophagus</keyword>
  <keyword>Gynecology</keyword>
  <keyword>Head and Neck</keyword>
  <keyword>Lung</keyword>
  <keyword>Pancreas</keyword>
  <keyword>Primary liver or liver metastases</keyword>
  <keyword>Prostate cancer</keyword>
  <keyword>Sarcoma</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>420 was the initial estimate but 158 subjects was the accrual</recruitment_details>
      <pre_assignment_details>158 subjects were enrolled.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>MRI for Treatment Planning or Follow up</title>
          <description>MRI for treatment planning for radiation therapy or those who have completed treatment and are receiving follow up care.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="158">158</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="158">158</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>MRI for Treatment Planning or Follow up</title>
          <description>MRI for treatment planning for radiation therapy or those who have completed treatment and are receiving follow up care.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="158"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="114"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <description>Enrollment open to both genders.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="85"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Successfully Contributing MRI Data</title>
        <description>We tested these Advanced MR protocols to evaluate which ones would best visualize the target region. This helped us determine the optimum MR SIM protocols for different sites that became clinical standard.</description>
        <time_frame>up to 4 weeks from imaging</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MRI for Treatment Planning or Follow up</title>
            <description>Patients aged 18 years and older of any race or gender with brain, head and neck, breast, lung, cervix, sarcoma, pancreatic, or prostate cancer undergoing MRI scans for radiation treatment planning and/or treatment follow-up at FMLH.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Successfully Contributing MRI Data</title>
          <description>We tested these Advanced MR protocols to evaluate which ones would best visualize the target region. This helped us determine the optimum MR SIM protocols for different sites that became clinical standard.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>MRI for Treatment Planning or Follow up</title>
          <description>MRI for treatment planning for radiation therapy or those who have completed treatment and are receiving follow up care.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="158"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="158"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ergun Ahunbay</name_or_title>
      <organization>Medical College of Wisconsin</organization>
      <phone>4148057898</phone>
      <email>eahunbay@mcw.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

